共 50 条
- [1] Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial [J]. LANCET, 2022, 399 (10337): : 1779 - 1789
- [2] Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial (vol 14, pg 281, 2014) [J]. LANCET INFECTIOUS DISEASES, 2014, 14 (04): : 269 - 269
- [3] Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial [J]. LANCET INFECTIOUS DISEASES, 2014, 14 (04): : 281 - 290
- [5] Topical imiquimod versus surgery for vulvar intraepithelial neoplasia: a multicentre, randomised, phase 3, non-inferiority trial (vol 399, pg 1790, 2022) [J]. LANCET, 2022, 400 (10359): : 1194 - 1194
- [6] The effect of a conditional cash transfer on HIV incidence in young women in rural South Africa (HPTN 068): a phase 3, randomised controlled trial (vol 4, pg e978, 2016) [J]. LANCET GLOBAL HEALTH, 2017, 5 (02): : E146 - E146
- [8] Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study (vol 8, pg e185, 2021) [J]. LANCET HIV, 2021, 8 (12): : E734 - E734